A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

642

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2030

Conditions
Breast Cancer
Interventions
DRUG

TQB2102 for Injection

TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer.

DRUG

Docetaxel combined + Trastuzumab +Pertuzumab

Positive control.

Trial Locations (25)

100050

NOT_YET_RECRUITING

Beijing Tiantan Hospital,Capital Medical University, Beijing

110000

NOT_YET_RECRUITING

Liaoning Provincial Cancer Hospital, Shenyang

116000

NOT_YET_RECRUITING

Affiliated Zhongshan Hospital Of Dalian University, Dalian

NOT_YET_RECRUITING

Affiliated Zhongshan Hospital Of Dalian University, Dalian

130000

NOT_YET_RECRUITING

The first hospital of Jilin University, Changchun

150081

NOT_YET_RECRUITING

Affiliated Cancer Hospital of Harbin Medical University, Harbin

201321

NOT_YET_RECRUITING

Fudan University shanghai cancer center, Shanghai

210029

NOT_YET_RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

230000

NOT_YET_RECRUITING

Anhui Provincial Cancer Hospital, Hefei

230001

NOT_YET_RECRUITING

Anhui Provincial Hospital, Hefei

250117

NOT_YET_RECRUITING

Cancer Hospital of Shandong First Medical University, Jinan

300060

NOT_YET_RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

NOT_YET_RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

410000

RECRUITING

Hunan Cancer Hospital, Changsha

434000

NOT_YET_RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

450000

NOT_YET_RECRUITING

The Third People's Hospital of Zhengzhou, Zhengzhou

457001

NOT_YET_RECRUITING

Puyang Oilfield General Hospital, Puyang

475099

NOT_YET_RECRUITING

Huaihe Hospital of Henan University, Kaifeng

515031

NOT_YET_RECRUITING

Shantou Central Hospital, Shantou

710000

NOT_YET_RECRUITING

The First Affiliated Hospital of Xi'An Jiaoting Yniversity, Xi'an

730050

NOT_YET_RECRUITING

Gansu Provincial Cancer Hospital, Lanzhou

NOT_YET_RECRUITING

Gansu Provincial Cancer Hospital, Lanzhou

831399

NOT_YET_RECRUITING

The Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi

030000

NOT_YET_RECRUITING

Shanxi Cancer Hospital, Taiyuan

044099

NOT_YET_RECRUITING

Yuncheng Central Hospital, Shanxi Province, Yuncheng

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY